A Phase 2/3 interventional study of arimoclomol and Placebo in Niemann-Pick Disease, Type C, sponsored by ZevraDenmark. Completed at 14 sites in 9 countries. Open to participants aged 2 Years to 18 Years. Per ClinicalTrials.gov, last updated 2024-11-29.
Sponsored by ZevraDenmark · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Niemann-Pick Disease, Type C with a site in United States — 6 open to participants now, 8 under way, 4 of them phase 3. Niemann-Pick Disease, Type C · United States.
Among the 23 studies in Niemann-Pick Disease, Type C with a site in United States, this one is the 7th largest by enrollment of the 17 interventional ones that give a count, is the only one that started in 2016, is one of 3 in phase 2/3, and was the 8th registered.
37 studies on the registry are indexed under Niemann-Pick Disease, Type C; 8 are open to participants now.
Browse Niemann-Pick Disease, Type C studies →6 of the 23 studies in Niemann-Pick Disease, Type C with a site in United States are open now. Recruiting first, the newest first:
Azafaros B.V. · Sites in United States, Argentina, Australia and 14 more countries
Ages 4+
Azafaros B.V. · Sites in United States, Argentina, Australia and 12 more countries
Ages 4+
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · Sites in United States
Ages 3 mo+
IntraBio Inc · Sites in United States, Australia, Czechia and 5 more countries
Ages 4+
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · Sites in United States
Ages 1 days–120 yrs · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 5 Niemann-Pick Disease, Type C studies recruiting now, 4 set no upper age limit and none stop at 75 or younger; 5 take children under 18; 1 takes healthy volunteers.
This study: 2 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 9 · Phase 3 8
First in 2006; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 50 is above the median of 21 across 27 interventional studies indexed under Niemann-Pick Disease, Type C.
Median enrollment 33 across the 17 interventional studies, 900 across the 5 observational. Of the 13 that completed or were terminated, 10 (77%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 23 have an industry lead sponsor. The 10 most frequent:
ZevraDenmark is the lead sponsor of 8 studies on the registry; 1 is open to participants now.
ZevraDenmark has 3 studies filed under Niemann-Pick Disease, Type C — fewer than ten, so there is no comparison to draw.
2 of the studies in Niemann-Pick Disease, Type C with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
| NCT05588167Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Establishment of Genomic and Phenotypic Database for Niemann-Pick Disease, Type C | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 23 studies in Niemann-Pick Disease, Type C with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A prospective, randomized, double-blind, placebo controlled therapeutic study in participants with confirmed diagnosis of Niemann-Pick disease type C (NPC).
The purpose of this study is to assess the efficacy and safety of arimoclomol (compared to placebo) when it is administered as an add-on therapy to the participant's current prescribed best routine clinical care; participant's routine clinical care may, or may not, include miglustat.
The CT-ORZY-NPC-002 study has been expanded to include an open label paediatric sub-study including participants aged 6 to \<24 months at study enrolment.
A prospective, randomized, double-blind, placebo controlled therapeutic study in participants with confirmed diagnosis of Niemann-Pick disease type C (NPC).
Participants must either 1) have completed Visit 2 (end of study [EOS]) of the CT-ORZY-NPC-001 study or 2) meet the eligibility criteria of this study including a requirement of stable treatment with miglustat for 6 months (if on miglustat therapy) prior to enrolment into the study.
Aim:
The purpose of this study is to assess the efficacy and safety of arimoclomol (compared to placebo) when it is administered as an add-on therapy to the participant's current prescribed best routine clinical care; participant's routine clinical care may, or may not, include miglustat.
Randomization:
Participants will be randomized to receive placebo or arimoclomol (with an allocation ratio of 1:2).
Pharmacokinetic evaluation (age below 12):
To confirm the selected dose, participants less than 12 years of age will undergo an arimoclomol single-dose pharmacokinetic (PK) evaluation before randomization and the start of continuous (multiple dosing) treatment.
Early Escape Clause:
In participants whose disease progression is too severe and/or too fast, the "early escape clause" will allow the Investigator to apply the escape route which implies that the participant can be treated with arimoclomol (as per blinded phase study schedule) and be followed up according to the study schedule or until the analysis of data from the controlled, 12-month blinded phase study period does not support the efficacy and/or safety of arimoclomol.
Study duration:
The duration of the blinded phase study period will be 12-months.
Following this, all participants will be offered to continue into the extension phase of the study where every participant will receive arimoclomol and be followed up and attend site visits every 6 months until 60 months after randomization. The extension phase runs until arimoclomol has received Regulatory Approval or until the analysis of data from the controlled, blinded phase 12-month study period does not support the efficacy and/or safety of arimoclomol.
The CT-ORZY-NPC-002 protocol has been updated to include a paediatric sub-study including new and naïve participants aged 6 to \<24 months at study enrolment.
Aim:
The purpose of the paediatric sub-study, is to assess the safety and tolerability of 36 months of open-label arimoclomol when administered as an add-on therapy to the participant's current prescribed best routine clinical care; participant's routine clinical care may, or may not, include miglustat.
The Paediatric sub-study will run at the open sites participating in the main study. A total of 3-5 participants are planned to be enrolled. All participants will be treated with arimoclomol.
Main Inclusion Criteria:
NPC diagnosis confirmed by:
Treated or not treated with miglustat;
Main Exclusion Criteria:
Arms and Intervention:
1 arm open label treatment with arimoclomol capsules 100 mg (dispersed in water) for oral administration (3 times daily). Doses: The dose in mL is based on the participant's weight in kg.
Randomization: Open Label
Pharmacokinetic: To confirm the selected dose, participants will undergo an arimoclomol single-dose pharmacokinetic (PK) evaluation before the start of continuous treatment.
Visit schedule time frame: Screening (V1); enrollment Week 1 (V2 baseline), Weeks 2 (V3), continuing visits at months 1 (V4), 3 (V5), 6 (V6), 9 (V7), 12 (V8), 15 (V8a), 18 (V9), 24 (V10), 30 (V11) and 36 (V12).
Primary objective: Safety and tolerability
Main Endpoint measures:
Safety data: Adverse events (AEs); Vital signs; Hematology; Clinical chemistry
Clinical status data: Clinical signs and symptoms captured through physical examination; Change from baseline in patient weight and height; Change in Bayley III score: Developmental delay scoring
Imaging data: Changes from baseline in the size of the liver and spleen assessed by ultrasound
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
EITHER NP-C participants who have entered the CT-ORZY-NPC-001 study and who have completed Visit 2 (EOS) of the CT-ORZY-NPC-001 study.
OR
NPC participants who did not enter or complete the CT-ORZY-NPC-001 study but are fulfilling all of criteria listed below:
◦Diagnosis of NPC1 or NPC2;
NPC diagnosis confirmed by:
Mutation in only one allele of NPC1 or NPC2 plus either positive filipin staining or elevated cholestane triol/oxysterols (>2 x ).
If a participant is under prescribed treatment with miglustat, it has to be under stable dose of the medication for at least 6 continuous months prior to inclusion in the CT-ORZY-NPC-002 study;
o If a participant has been discontinued from prescribed treatment with miglustat, they must have been discontinued for at least 3 continuous months prior to inclusion in the CT-ORZY-NPC-002 study;
Ability to walk either independently or with assistance.
Highly effective birth control methods include: Combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal or transdermal); progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable or implantable); intrauterine device (IUD); intrauterine hormone-releasing system (IUS); bilateral tubal occlusion; and vasectomised partner.
All sexually active male participants with female partners of child-bearing potential (post-menarchal) must use a condom with or without spermicide in addition to the birth control used by their partners during the study and until 3 months after the last dose of IMP.
Sexual abstinence is considered a highly effective birth control method only if it is defined as refraining from heterosexual intercourse during the study and for 1 week after the last dose of IMP (for female participants of child-bearing potential) and for 3 months after the last dose of IMP (for male participants with female partners of child-bearing potential). The reliability of sexual abstinence needs to be evaluated by the Investigator in relation to the duration of the clinical trial and the preferred and usual lifestyle of the participant.
•Ability to comply with the protocol-specified procedures/evaluations and scheduled visits.
Exclusion Criteria:
This includes treatment with any investigational drug during the study in an attempt to treat NP-C;
For participants who have not completed the CT-ORZY-NPC-001 study, fulfilling any of the criteria listed below:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants less than 12 years received a single oral dose of arimoclomol capsule, based on participant's body weight, on Day 1.
Drug: arimoclomol
Participants received arimoclomol capsules orally three times a day (TID) for 12 months. The dose was 31-124 mg arimoclomol base TID (equivalent to 50-200 mg arimoclomol citrate TID), based on participant's body weight.
Drug: arimoclomol
Participants received matching placebo capsules (with regard to weight, appearance, smell, flavor etc.) orally TID for 12 months.
Drug: Placebo
Change From Baseline in the Niemann-Pick Disease Type C (NPC) Disease Severity Assessed Based on the 5-domain NPCCSS Total Scores
NPC disease severity was assessed based on the 5-domain NPC Clinical Severity Scale (NPCCSS). The 5-domain NPCCSS focuses on domains identified by participants, caregivers, and NPC experts as the most clinically relevant when assessing disease progression in NPC: Ambulation, fine motor skills, swallow, cognition, and speech. The scale is derived from the original 17-domain NPCCSS. Each domain is rated on a scale of 0-5 based on clinical assessments, observations, and interviews with participants/caregiver. The total score is a sum of the score of each of the 5 domains and ranges from 0-25, with a higher score indicating more severe clinical impairment.
Time frame: Baseline to Month 12
Percentage of Responders in Clinical Global Impression Scale of Improvement (CGI-I) - Defined as Percentage of Participants Where the CGI-I Score Remains Stable or Shows Improvement (This Outcome Measure Was Considered Co-primary by the FDA)
The CGI-I is a 7-point scale that rates total improvement of participant's condition. The clinician rates the participants from 1=Very much improved, 2=Much improved, 3=Minimally improved, 4=No change, 5=Minimally worse, 6=Much worse, or 7=Very much worse. Scores thus range from 1-7 with lower scores indicating greater improvement. Responders were the participants with a score of 1 or 2 at Month 12.
Time frame: Month 12
Percentage of Responders in 5-domain NPCCSS - Defined as Participants Where the 5-domain NPCCSS Score Remains Stable or Improves as Compared to Baseline
NPC disease severity was assessed based on the 5-domain NPC Clinical Severity Scale (NPCCSS). The 5-domain NPCCSS focuses on domains identified by participants, caregivers, and NPC experts as the most clinically relevant when assessing disease progression in NPC: Ambulation, fine motor skills, swallow, cognition, and speech. The scale is derived from the original 17-domain NPCCSS. Each domain is rated on a scale of 0-5 based on clinical assessments, observations, and interviews with participants/caregiver. The total score is a sum of the score of each of the 5 domains and ranges from 0-25, with a higher score indicating more severe clinical impairment. Stable was defined as a participant's total score for the 5 domains being the same at month 12 as at baseline. Improvement was defined as a participant's total score at month 12 being lower than at baseline.
Time frame: Baseline to Month 12
Time to Worsening
Time to worsening was defined as the time until the participant reached the predefined minimal clinically important difference (MCID) of 2 points compared to baseline on the 5-domain NPC Clinical Severity Scale (NPCCSS). The 5-domain NPCCSS focuses on domains identified by participants, caregivers, and NPC experts as the most clinically relevant when assessing disease progression in NPC: Ambulation, fine motor skills, swallow, cognition, and speech. The scale is derived from the original 17-domain NPCCSS. Each domain is rated on a scale of 0-5 based on clinical assessments, observations, and interviews with participants/caregiver. The total score is a sum of the score of each of the 5 domains and ranges from 0-25, with a higher score indicating more severe clinical impairment. The values reported per group are the 25th percentile Kaplan-Meier estimates and 95% confidence interval.
Time frame: Baseline to Month 12
Percentage of Participants With Worsening
Worsening was defined as participants that have reached the predefined MCID of 2 points on their 5-domain NPC Clinical Severity Scale (NPCCSS). The 5-domain NPCCSS focuses on domains identified by participants, caregivers, and NPC experts as the most clinically relevant when assessing disease progression in NPC: Ambulation, fine motor skills, swallow, cognition, and speech. The scale is derived from the original 17-domain NPCCSS. Each domain is rated on a scale of 0-5 based on clinical assessments, observations, and interviews with participants/caregiver. The total score is a sum of the score of each of the 5 domains and ranges from 0-25, with a higher score indicating more severe clinical impairment.
Time frame: Months 6 and 12
Change From Baseline in 17-domain NPCCSS Apart From Hearing Domains (i.e. Hearing and Auditory Brainstem Response)
The NPC Clinical Severity Scale (NPCCSS) is a disease-specific, clinician-reported outcome measure developed to characterize and quantify NPC disease progression. The 17-domain NPCCSS includes clinical signs and symptoms in nine major and eight minor domains, which are rated on scales of 0-5 (for the major domains) or 0-2 (for the minor domains). The total score is the sum of the score of each of the 17 domains and ranges from 0 to 61, with a high score indicating a more severe clinical impairment.
Time frame: Baseline to 6 and 12 months
Change From Baseline in 5-domain NPCCSS Score
The 5-domain NPC Clinical Severity Scale (NPCCSS) focuses on domains identified by participants, caregivers, and NPC experts as the most clinically relevant when assessing disease progression in NPC: Ambulation, fine motor skills, swallow, cognition, and speech. The scale is derived from the original 17-domain NPCCSS. Each domain is rated on a scale of 0-5 based on clinical assessments, observations, and interviews with participants/caregiver. The total score is a sum of the score of each of the 5 domains and ranges from 0-25, with a higher score indicating more severe clinical impairment.
Time frame: Baseline to 6 months
Changes From Baseline in Each Individual Domain of the NPCCSS
The NPC Clinical Severity Scale (NPCCSS) is a disease-specific, clinician-reported outcome measure developed to characterize and quantify disease progression. The 17-domain NPCCSS includes clinical signs and symptoms in nine major (ambulation, cognition, eye movement, fine motor, hearing, memory, seizures, speech, swallowing,) and eight minor (auditory brainstem response, behavior, gelastic cataplexy, hyperreflexia, incontinence, narcolepsy, psychiatric, respiratory problems) domains, which are rated on scales of 0-5 (for the major domains) or 0-2 (for the minor domains). A higher score indicates a more severe clinical impairment.
Time frame: Baseline to 6 and 12 months
Change From Baseline in the NPC Clinical Database (NPC-CDB) Score (Modified "Stampfer Score")
The NPC Clinical Database (NPC-cdb) score aims to reflect the current clinical status of the participant. The NPC-cdb score represents both historical symptoms and a current status. The test consists of ten areas: visceral signs, development, motor function, ocular-motor abnormalities, seizures/cataplexy/narcolepsy, cognitive abilities and memory, behavioral and psychiatric abnormalities, speech, hearing, and abilities in daily life. The current status score is a severity-weighted sum of 72 symptoms considered as disease-relevant at the time of assessment. Each symptom contributes with a score between 1 and 5, the maximum score is 125. An increase in score reflects a reduction in the participant's abilities.
Time frame: Baseline to 6 and 12 months
Percentage of Participants With Change From Baseline in Quality of Life (EQ-5D-Y)
The EQ-5D-Y descriptive system includes 5 descriptive items: Mobility, self-care, doing usual activities, having pain or discomfort, and feeling anxiety or depressed. Each dimension has 3 levels: No problems, some problems, and a lot of problems. The change in the 5 individual items of the EQ-5D-Y per participant was explored by using the pareto principle at 6 and 12 months to show the number (%) of participants who felt: * Better (better on at least one dimension and no worse in any other dimension), * Worse (worse in at least one dimension, and no better in any other dimension)
Time frame: Baseline to 6 and 12 months
Change From Baseline in the Scale for Assessment and Rating of Ataxia (SARA) Score
The SARA included eight items reflecting neurologic manifestations of cerebellar ataxia. The test provides a direct and simple description of motor function in a participant. The test consists of 8 test items: gait, stance, sitting, speech disturbance, finger chase, nose-finger test, fast alternating hand movements, and heel-shin slide. The total score of the 8 items ranges from 0 (normal cerebellar function) to 40 (not able to perform any of the test items).
Time frame: Baseline to 6 and 12 months
Change From Baseline in the Time Spent to Complete the Nine-Hole Peg Test (9HPT)
The 9HPT test is a direct and simple measurement of fine motor coordination function, eye/hand coordination, and the ability to follow a simple direction. The 9HPT is a timed test in which nine pegs are inserted and removed from nine holes in the pegboard. Both hands are tested starting with the dominant hand. The time spent in completing the 9 HPT using each hand was recorded.
Time frame: Baseline to 6 and 12 months
Percentage of Participants Within Each Severity Category of the Clinical Global Impression Scale of Severity (CGI-S)
The CGI-S is a 7-point scale that requires the clinician to rate the severity of the participant's illness at the time of assessment. A rating of 1 is considered normal, or with the least severe symptoms, a rating of 7 is extremely ill, or the worst symptoms. Scores thus range from 1-7 with lower scores indicating less severe disease.
Time frame: Months 6 and 12
Percentage of Participants Within Each Category of the Clinical Global Impression Scale of Improvement (CGI-I)
The CGI-I is a 7-point scale that rates total improvement of participant's condition. The clinician rates the participants from 1=Very much improved, 2=Much improved, 3=Minimally improved, 4=No change, 5=Minimally worse, 6=Much worse, or 7=Very much worse. Scores thus range from 1-7 with lower scores indicating greater improvement.
Time frame: Months 6 and 12
The study was conducted at 14 sites in Denmark, France, Germany, Italy, Poland, Spain, Switzerland, United Kingdom, and United States.
| Milestone | Arimoclomol Single PK Dose | Arimoclomol (12-month Double-blind Phase) | Placebo (12-month Double-blind Phase) |
|---|---|---|---|
| Started | 28 | 0 | 0 |
| Completed | 27 | 0 | 0 |
| Not completed | 1 | 0 | 0 |
| Withdrew: Screening failure | 1 | 0 | 0 |
| Milestone | Arimoclomol Single PK Dose | Arimoclomol (12-month Double-blind Phase) | Placebo (12-month Double-blind Phase) |
|---|---|---|---|
| Started | 0 | 34 | 16 |
| Completed | 0 | 27 | 15 |
| Not completed | 0 | 7 | 1 |
| Withdrew: Early escape | 0 | 2 | 0 |
| Withdrew: Participant's parents/legal guardian have withdrawn informed consent | 0 | 1 | 0 |
| Withdrew: Safety reasons | 0 | 3 | 0 |
| Withdrew: Death | 0 | 1 | 0 |
| Withdrew: Participant meets criteria for imp administration to be stopped and subsequent withdrawal | 0 | 0 | 1 |
NPC disease severity was assessed based on the 5-domain NPC Clinical Severity Scale (NPCCSS). The 5-domain NPCCSS focuses on domains identified by participants, caregivers, and NPC experts as the most clinically relevant when assessing disease progression in NPC: Ambulation, fine motor skills, swallow, cognition, and speech. The scale is derived from the original 17-domain NPCCSS. Each domain is rated on a scale of 0-5 based on clinical assessments, observations, and interviews with participants/caregiver. The total score is a sum of the score of each of the 5 domains and ranges from 0-25, with a higher score indicating more severe clinical impairment.
| score on a scale | Arimoclomol (12-month Double-blind Phase) | Placebo (12-month Double-blind Phase) |
|---|---|---|
| Change From Baseline in the Niemann-Pick Disease Type C (NPC) Disease Severity Assessed Based on the 5-domain NPCCSS Total Scores | 0.76 (-0.05 to 1.56) | 2.15 (1.05 to 3.25) |
The CGI-I is a 7-point scale that rates total improvement of participant's condition. The clinician rates the participants from 1=Very much improved, 2=Much improved, 3=Minimally improved, 4=No change, 5=Minimally worse, 6=Much worse, or 7=Very much worse. Scores thus range from 1-7 with lower scores indicating greater improvement. Responders were the participants with a score of 1 or 2 at Month 12.
| percentage of responders | Arimoclomol (12-month Double-blind Phase) | Placebo (12-month Double-blind Phase) |
|---|---|---|
| Percentage of Responders in Clinical Global Impression Scale of Improvement (CGI-I) - Defined as Percentage of Participants Where the CGI-I Score Remains Stable or Shows Improvement (This Outcome Measure Was Considered Co-primary by the FDA) | 58.8 | 56.3 |
NPC disease severity was assessed based on the 5-domain NPC Clinical Severity Scale (NPCCSS). The 5-domain NPCCSS focuses on domains identified by participants, caregivers, and NPC experts as the most clinically relevant when assessing disease progression in NPC: Ambulation, fine motor skills, swallow, cognition, and speech. The scale is derived from the original 17-domain NPCCSS. Each domain is rated on a scale of 0-5 based on clinical assessments, observations, and interviews with participants/caregiver. The total score is a sum of the score of each of the 5 domains and ranges from 0-25, with a higher score indicating more severe clinical impairment. Stable was defined as a participant's total score for the 5 domains being the same at month 12 as at baseline. Improvement was defined as a participant's total score at month 12 being lower than at baseline.
| percentage of responders | Arimoclomol (12-month Double-blind Phase) | Placebo (12-month Double-blind Phase) |
|---|---|---|
| Percentage of Responders in 5-domain NPCCSS - Defined as Participants Where the 5-domain NPCCSS Score Remains Stable or Improves as Compared to Baseline | 50.0 | 37.5 |
Time to worsening was defined as the time until the participant reached the predefined minimal clinically important difference (MCID) of 2 points compared to baseline on the 5-domain NPC Clinical Severity Scale (NPCCSS). The 5-domain NPCCSS focuses on domains identified by participants, caregivers, and NPC experts as the most clinically relevant when assessing disease progression in NPC: Ambulation, fine motor skills, swallow, cognition, and speech. The scale is derived from the original 17-domain NPCCSS. Each domain is rated on a scale of 0-5 based on clinical assessments, observations, and interviews with participants/caregiver. The total score is a sum of the score of each of the 5 domains and ranges from 0-25, with a higher score indicating more severe clinical impairment. The values reported per group are the 25th percentile Kaplan-Meier estimates and 95% confidence interval.
| months | Arimoclomol (12-month Double-blind Phase) | Placebo (12-month Double-blind Phase) |
|---|---|---|
| Time to Worsening | 5.2 (2.9 to 12.0) | 5.5 (1.0 to 6.5) |
Worsening was defined as participants that have reached the predefined MCID of 2 points on their 5-domain NPC Clinical Severity Scale (NPCCSS). The 5-domain NPCCSS focuses on domains identified by participants, caregivers, and NPC experts as the most clinically relevant when assessing disease progression in NPC: Ambulation, fine motor skills, swallow, cognition, and speech. The scale is derived from the original 17-domain NPCCSS. Each domain is rated on a scale of 0-5 based on clinical assessments, observations, and interviews with participants/caregiver. The total score is a sum of the score of each of the 5 domains and ranges from 0-25, with a higher score indicating more severe clinical impairment.
| percentage of participants | Arimoclomol (12-month Double-blind Phase) | Placebo (12-month Double-blind Phase) |
|---|---|---|
| Worsening at Month 6 | 35.3 | 50.0 |
| Worsening at Month 12 | 44.1 | 43.8 |
The NPC Clinical Severity Scale (NPCCSS) is a disease-specific, clinician-reported outcome measure developed to characterize and quantify NPC disease progression. The 17-domain NPCCSS includes clinical signs and symptoms in nine major and eight minor domains, which are rated on scales of 0-5 (for the major domains) or 0-2 (for the minor domains). The total score is the sum of the score of each of the 17 domains and ranges from 0 to 61, with a high score indicating a more severe clinical impairment.
| score on a scale | Arimoclomol (12-month Double-blind Phase) | Placebo (12-month Double-blind Phase) |
|---|---|---|
| Change at Month 6 | 0.53 (-0.85 to 1.90) | 2.22 (0.33 to 4.10) |
| Change at Month 12 | 1.20 (-0.40 to 2.79) | 2.81 (0.75 to 4.87) |
The 5-domain NPC Clinical Severity Scale (NPCCSS) focuses on domains identified by participants, caregivers, and NPC experts as the most clinically relevant when assessing disease progression in NPC: Ambulation, fine motor skills, swallow, cognition, and speech. The scale is derived from the original 17-domain NPCCSS. Each domain is rated on a scale of 0-5 based on clinical assessments, observations, and interviews with participants/caregiver. The total score is a sum of the score of each of the 5 domains and ranges from 0-25, with a higher score indicating more severe clinical impairment.
| score on a scale | Arimoclomol (12-month Double-blind Phase) | Placebo (12-month Double-blind Phase) |
|---|---|---|
| Change From Baseline in 5-domain NPCCSS Score | 0.48 (-0.05 to 1.02) | 1.60 (0.86 to 2.34) |
The NPC Clinical Severity Scale (NPCCSS) is a disease-specific, clinician-reported outcome measure developed to characterize and quantify disease progression. The 17-domain NPCCSS includes clinical signs and symptoms in nine major (ambulation, cognition, eye movement, fine motor, hearing, memory, seizures, speech, swallowing,) and eight minor (auditory brainstem response, behavior, gelastic cataplexy, hyperreflexia, incontinence, narcolepsy, psychiatric, respiratory problems) domains, which are rated on scales of 0-5 (for the major domains) or 0-2 (for the minor domains). A higher score indicates a more severe clinical impairment.
| score on a scale | Arimoclomol (12-month Double-blind Phase) | Placebo (12-month Double-blind Phase) |
|---|---|---|
| Ambulation: Baseline | 2.5 ± 1.6 | 2.2 ± 1.6 |
| Ambulation: Change at Month 6 | 0.1 ± 0.4 | 0.3 ± 1.0 |
| Ambulation: Change at Month 12 | 0.3 ± 0.5 | 0.3 ± 0.9 |
| Speech: Baseline | 2.2 ± 1.6 | 1.6 ± 1.2 |
| Speech: Change at Month 6 | 0.1 ± 0.5 | 0.1 ± 0.3 |
| Speech: Change at Month 12 | -0.2 ± 1.0 | 0.3 ± 0.8 |
| Swallow: Baseline | 1.9 ± 1.7 | 1.3 ± 1.7 |
| Swallow: Change at Month 6 | 0.1 ± 1.1 | 0.4 ± 1.0 |
| Swallow: Change at Month 12 | 0.1 ± 1.1 | 0.6 ± 1.0 |
| Fine Motor Skills: Baseline | 2.8 ± 1.8 | 1.9 ± 1.8 |
| Fine Motor Skills: Change at Month 6 | 0.1 ± 0.7 | 0.5 ± 1.1 |
| Fine Motor Skills: Change at Month 12 | 0.2 ± 0.8 | 0.6 ± 1.3 |
| Cognition: Baseline | 2.8 ± 1.3 | 2.5 ± 1.5 |
| Cognition: Change at Month 6 | 0.2 ± 0.5 | 0.3 ± 0.8 |
| Cognition: Change at Month 12 | 0.3 ± 0.6 | 0.1 ± 0.6 |
| Eye Movement: Baseline | 2.2 ± 1.2 | 2.1 ± 1.1 |
| Eye Movement: Change at Month 6 | 0.0 ± 0.6 | -0.1 ± 0.7 |
| Eye Movement: Change at Month 12 | 0.2 ± 0.9 | -0.1 ± 0.6 |
| Memory: Baseline | 1.9 ± 1.4 | 1.3 ± 1.5 |
| Memory: Change at Month 6 | 0.1 ± 0.5 | 0.2 ± 1.1 |
| Memory: Change at Month 12 | 0.1 ± 0.5 | 0.3 ± 0.8 |
| Seizures: Baseline | 1.9 ± 1.9 | 1.3 ± 1.8 |
| Seizures: Change at Month 6 | -0.1 ± 0.8 | 0.0 ± 1.5 |
| Seizures: Change at Month 12 | 0.3 ± 0.8 | -0.1 ± 1.7 |
| Hearing: Baseline | 0.4 ± 1.0 | 0.0 ± 0.0 |
| Hearing: Change at Month 6 | -0.2 ± 0.8 | 0.0 ± 0.0 |
| Hearing: Change at Month 12 | 0.0 ± 0.0 | 0.3 ± 0.8 |
| Auditory Brainstem Response: Baseline | 0.2 ± 0.4 | 0.1 ± 0.4 |
| Auditory Brainstem Response: Change at Month 6 | 0.0 ± 0.0 | 0.2 ± 0.4 |
| Auditory Brainstem Response: Change at Month 12 | 0.0 ± 0.0 | 0.0 ± 0.0 |
| Behavior: Baseline | 0.4 ± 0.6 | 0.4 ± 0.6 |
| Behavior: Change at Month 6 | 0.0 ± 0.5 | -0.1 ± 0.5 |
| Behavior: Change at Month 12 | 0.1 ± 0.6 | -0.2 ± 0.4 |
| Gelastic Cataplexy: Baseline | 0.8 ± 0.9 | 0.4 ± 0.8 |
| Gelastic Cataplexy: Change at Month 6 | 0.1 ± 0.5 | 0.3 ± 0.6 |
| Gelastic Cataplexy: Change at Month 12 | 0.2 ± 0.6 | 0.3 ± 0.6 |
| Hyperreflexia: Baseline | 1.0 ± 0.7 | 1.1 ± 0.9 |
| Hyperreflexia: Change at Month 6 | -0.0 ± 0.5 | 0.2 ± 0.6 |
| Hyperreflexia: Change at Month 12 | 0.1 ± 0.7 | 0.1 ± 0.5 |
| Incontinence: Baseline | 1.0 ± 0.8 | 0.8 ± 0.9 |
| Incontinence: Change at Month 6 | -0.1 ± 0.4 | 0.1 ± 0.5 |
| Incontinence: Change at Month 12 | -0.0 ± 0.4 | 0.1 ± 0.9 |
| Narcolepsy (NARCO): Baseline | 0.1 ± 0.4 | 0.3 ± 0.7 |
| Narcolepsy (NARCO): Change at Month 6 | 0.0 ± 0.4 | -0.1 ± 0.3 |
| Narcolepsy (NARCO): Change at Month 12 | -0.1 ± 0.4 | -0.1 ± 0.3 |
| Psychiatric: Baseline | 0.1 ± 0.4 | 0.1 ± 0.5 |
| Psychiatric: Change at Month 6 | -0.0 ± 0.3 | 0.1 ± 0.6 |
| Psychiatric: Change at Month 12 | 0.0 ± 0.3 | 0.0 ± 0.4 |
| Respiratory: Baseline | 0.1 ± 0.3 | 0.0 ± 0.0 |
| Respiratory: Change at Month 6 | 0.0 ± 0.5 | 0.1 ± 0.3 |
| Respiratory: Change at Month 12 | 0.1 ± 0.5 | 0.2 ± 0.4 |
The NPC Clinical Database (NPC-cdb) score aims to reflect the current clinical status of the participant. The NPC-cdb score represents both historical symptoms and a current status. The test consists of ten areas: visceral signs, development, motor function, ocular-motor abnormalities, seizures/cataplexy/narcolepsy, cognitive abilities and memory, behavioral and psychiatric abnormalities, speech, hearing, and abilities in daily life. The current status score is a severity-weighted sum of 72 symptoms considered as disease-relevant at the time of assessment. Each symptom contributes with a score between 1 and 5, the maximum score is 125. An increase in score reflects a reduction in the participant's abilities.
| score on a scale | Arimoclomol (12-month Double-blind Phase) | Placebo (12-month Double-blind Phase) |
|---|---|---|
| Change at Month 6 | -0.38 (-3.30 to 2.54) | 4.71 (0.49 to 8.93) |
| Change at Month 12 | 1.85 (-2.16 to 5.86) | 4.88 (-0.63 to 10.39) |
The EQ-5D-Y descriptive system includes 5 descriptive items: Mobility, self-care, doing usual activities, having pain or discomfort, and feeling anxiety or depressed. Each dimension has 3 levels: No problems, some problems, and a lot of problems. The change in the 5 individual items of the EQ-5D-Y per participant was explored by using the pareto principle at 6 and 12 months to show the number (%) of participants who felt: * Better (better on at least one dimension and no worse in any other dimension), * Worse (worse in at least one dimension, and no better in any other dimension)
| percentage of participants | Arimoclomol (12-month Double-blind Phase) | Placebo (12-month Double-blind Phase) |
|---|---|---|
| Better: Change at Month 6 | 16.7 | 26.7 |
| Worse: Change at Month 6 | 40.0 | 46.7 |
| Better: Change at Month 12 | 25.9 | 40.0 |
| Worse: Change at Month 12 | 44.4 | 20.0 |
The SARA included eight items reflecting neurologic manifestations of cerebellar ataxia. The test provides a direct and simple description of motor function in a participant. The test consists of 8 test items: gait, stance, sitting, speech disturbance, finger chase, nose-finger test, fast alternating hand movements, and heel-shin slide. The total score of the 8 items ranges from 0 (normal cerebellar function) to 40 (not able to perform any of the test items).
| score on a scale | Arimoclomol (12-month Double-blind Phase) | Placebo (12-month Double-blind Phase) |
|---|---|---|
| Change at 6 months | 0.79 (-0.16 to 1.75) | 0.05 (-1.29 to 1.40) |
| Change at 12 months | 1.06 (-0.17 to 2.29) | 0.78 (-0.90 to 2.47) |
The 9HPT test is a direct and simple measurement of fine motor coordination function, eye/hand coordination, and the ability to follow a simple direction. The 9HPT is a timed test in which nine pegs are inserted and removed from nine holes in the pegboard. Both hands are tested starting with the dominant hand. The time spent in completing the 9 HPT using each hand was recorded.
| seconds | Arimoclomol (12-month Double-blind Phase) | Placebo (12-month Double-blind Phase) |
|---|---|---|
| Dominant Hand: Change at 6 months | 1.54 (-24.98 to 28.06) | 11.88 (-20.88 to 44.64) |
| Non-dominant Hand: Change at 6 months | 0.60 (-27.25 to 28.45) | 16.46 (-17.07 to 50.00) |
| Dominant Hand: Change at 12 months | -3.29 (-15.56 to 8.98) | -6.49 (-20.34 to 7.37) |
| Non-dominant Hand: Change at 12 months | 11.68 (-14.89 to 38.25) | 17.59 (-13.24 to 48.42) |
The CGI-S is a 7-point scale that requires the clinician to rate the severity of the participant's illness at the time of assessment. A rating of 1 is considered normal, or with the least severe symptoms, a rating of 7 is extremely ill, or the worst symptoms. Scores thus range from 1-7 with lower scores indicating less severe disease.
| percentage of participants | Arimoclomol (12-month Double-blind Phase) | Placebo (12-month Double-blind Phase) |
|---|---|---|
| Month 6: Normal, not ill at all | 0 | 0 |
| Month 6: Borderline ill | 10.3 | 14.3 |
| Month 6: Mildly ill | 27.6 | 28.6 |
| Month 6: Moderately ill | 10.3 | 35.7 |
| Month 6: Markedly ill | 31.0 | 0 |
| Month 6: Severely ill | 20.7 | 14.3 |
| Month 6: Most extremely ill participants | 0 | 7.1 |
| Month 12: Normal, not ill at all | 0 | 0 |
| Month 12: Borderline ill | 7.4 | 6.7 |
| Month 12: Mildly ill | 29.6 | 26.7 |
| Month 12: Moderately ill | 11.1 | 33.3 |
| Month 12: Markedly ill | 29.6 | 6.7 |
| Month 12: Severely ill | 22.2 | 26.7 |
| Month 12: Most extremely ill participants | 0 | 0 |
The CGI-I is a 7-point scale that rates total improvement of participant's condition. The clinician rates the participants from 1=Very much improved, 2=Much improved, 3=Minimally improved, 4=No change, 5=Minimally worse, 6=Much worse, or 7=Very much worse. Scores thus range from 1-7 with lower scores indicating greater improvement.
| percentage of participants | Arimoclomol (12-month Double-blind Phase) | Placebo (12-month Double-blind Phase) |
|---|---|---|
| Month 6: Very Much Improved | 3.4 | 0 |
| Month 6: Much Improved | 0 | 0 |
| Month 6: Minimally Improved | 24.1 | 25.0 |
| Month 6: No Change | 37.9 | 25.0 |
| Month 6: Minimally Worse | 27.6 | 33.3 |
| Month 6: Much Worse | 6.9 | 16.7 |
| Month 6: Very Much Worse | 0 | 0 |
| Month 12: Very Much Improved | 0 | 0 |
| Month 12: Much Improved | 3.7 | 6.7 |
| Month 12: Minimally Improved | 18.5 | 33.3 |
| Month 12: No Change | 51.9 | 20.0 |
| Month 12: Minimally Worse | 14.8 | 13.3 |
| Month 12: Much Worse | 7.4 | 26.7 |
| Month 12: Very Much Worse | 3.7 | 0 |
Collected over From first dose of study drug up to last dose of blinded study treatment (Month 12). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arimoclomol Single PK Dose | 0/28 (0%) | 2/28 (7.1%) | 4/28 (14.3%) |
| Arimoclomol (12-month Double-blind Phase) | 1/34 (2.9%) | 5/34 (14.7%) | 30/34 (88.2%) |
| Placebo (12-month Double-blind Phase) | 0/16 (0%) | 6/16 (37.5%) | 13/16 (81.3%) |
| Event | Arimoclomol Single PK Dose | Arimoclomol (12-month Double-blind Phase) | Placebo (12-month Double-blind Phase) |
|---|---|---|---|
| PneumoniaInfections and infestations | 1/28 | 0/34 | 2/16 |
| EpilepsyNervous system disorders | 0/28 | 0/34 | 2/16 |
| DiarrhoeaGastrointestinal disorders | 0/28 | 0/34 | 1/16 |
| Lower Respiratory Tract InfectionInfections and infestations | 0/28 | 0/34 | 1/16 |
| Craniocerebral InjuryInjury, poisoning and procedural complications | 0/28 | 0/34 | 1/16 |
| LacerationInjury, poisoning and procedural complications | 0/28 | 0/34 | 1/16 |
| HypophagiaMetabolism and nutrition disorders | 0/28 | 0/34 | 1/16 |
| Foot DeformityMusculoskeletal and connective tissue disorders | 0/28 | 0/34 | 1/16 |
| Respiratory Tract InfectionInfections and infestations | 0/28 | 0/34 | 1/16 |
| UrticariaSkin and subcutaneous tissue disorders | 0/28 | 2/34 | 0/16 |
| Event | Arimoclomol Single PK Dose | Arimoclomol (12-month Double-blind Phase) | Placebo (12-month Double-blind Phase) |
|---|---|---|---|
| VomitingGastrointestinal disorders | 0/28 | 8/34 | 4/16 |
| NasopharyngitisInfections and infestations | 0/28 | 2/34 | 4/16 |
| ConstipationGastrointestinal disorders | 0/28 | 7/34 | 3/16 |
| DiarrhoeaGastrointestinal disorders | 0/28 | 7/34 | 2/16 |
| PyrexiaGeneral disorders | 1/28 | 6/34 | 3/16 |
| Upper Respiratory Tract InfectionInfections and infestations | 1/28 | 6/34 | 1/16 |
| RhinitisInfections and infestations | 0/28 | 5/34 | 2/16 |
| Weight DecreasedInvestigations | 0/28 | 5/34 | 0/16 |
| BronchitisInfections and infestations | 0/28 | 4/34 | 2/16 |
| Ear InfectionInfections and infestations | 0/28 | 0/34 | 2/16 |
Full Analysis Set (FAS) included those participants who were randomized and who had received at least one dose of randomized treatment medication.
| Age, Continuous(years) | Arimoclomol (12-month Double-blind Phase) | Placebo (12-month Double-blind Phase) | Total |
|---|---|---|---|
| Mean | 11.5 ± 5.4 | 10.2 ± 4.1 | 11.1 ± 5.0 |
| Sex: Female, Male(Participants) | Arimoclomol (12-month Double-blind Phase) | Placebo (12-month Double-blind Phase) | Total |
|---|---|---|---|
| Female | 17 | 9 | 26 |
| Male | 17 | 7 | 24 |
| Ethnicity (NIH/OMB)(Participants) | Arimoclomol (12-month Double-blind Phase) | Placebo (12-month Double-blind Phase) | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 0 | 2 |
| Not Hispanic or Latino | 32 | 16 | 48 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Arimoclomol (12-month Double-blind Phase) | Placebo (12-month Double-blind Phase) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 0 | 0 | 0 |
| White | 32 | 13 | 45 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 1 | 2 |
| Age at Diagnosis of First Neurological Symptom(years) | Arimoclomol (12-month Double-blind Phase) | Placebo (12-month Double-blind Phase) | Total |
|---|---|---|---|
| Mean | 5.05 ± 3.43 | 5.22 ± 3.87 | 5.10 ± 3.54 |
| 5-domain Niemann-Pick Disease Type C Clinical Severity Scale (NPCCSS) Score(score on a scale) | Arimoclomol (12-month Double-blind Phase) | Placebo (12-month Double-blind Phase) | Total |
|---|---|---|---|
| Mean | 12.1 ± 6.9 | 9.4 ± 6.4 | 11.2 ± 6.8 |
| 17-domain NPCCSS Except Hearing Domains(score on a scale) | Arimoclomol (12-month Double-blind Phase) | Placebo (12-month Double-blind Phase) | Total |
|---|---|---|---|
| Mean | 21.2 ± 11.5 | 17.2 ± 11.3 | 19.9 ± 11.4 |
| Participants Currently Treated With Miglustat(Participants) | Arimoclomol (12-month Double-blind Phase) | Placebo (12-month Double-blind Phase) | Total |
|---|---|---|---|
| Yes | 26 | 13 | 39 |
| No | 8 | 3 | 11 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2016 to primary completion in Jun 2018, 24 months.
Results were first posted in Jun 2023, 4 years 11 months after primary completion. A results delay was requested in May 2019.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Arimoclomol
Niemann-Pick Disease, Type C →
ZevraDenmark